ADARx Pharmaceuticals, Inc. (ADRX)
ADRXNASDAQ-GSBiotechnology: Pharmaceutical Preparations
$14.00
-0.2000 (-1.41%) today
Closed, Nov 16, 4:00 PM ET
- Market cap
- $1.56bn
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $12.50 to $23.21
- Average volume
- –
- Previous close
- $14.20
Analysts
4 coveringBuy4 buy, 0 hold, 0 sell
Targets a year out average $35.00, +150.0% from here
Earnings
next estimate $-0.3800Next report
Sep 2026
-335.0%
estimate reported, and the surprise
News
3 latestThe company
ADARx Pharmaceuticals, Inc. is a late-clinical stage biotechnology company focused on developing next-generation RNA therapeutics designed to treat a broad spectrum of diseases. The Company is focused on advancing and expanding its pipeline of highly potent, selective and durable small interfering RNA ('siRNA') therapeutic candidates, including three clinical-stage programs and two advanced preclinical programs. ADARx's three hepatic-targeted programs are agazisiran, onvuzosiran and ADX-626, and its two extrahepatic-targeted programs are ADX-077 and ADX-199. Beyond its named programs, ADARx plans to continue to leverage its proprietary technologies to strategically expand its pipeline of next-generation siRNA therapeutics. ADARx's goal is to control the expression of specific disease drivers with highly selective RNA targeted therapies, delivering life-changing treatments for patients with urgent unmet medical needs.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-GS
- Region
- North America
- Website
- www.adarx.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.